Virco was a biotech company located in Mechelen, Belgium. It was founded in 1995, and was acquired by Johnson & Johnson in 2002. It provided quantitative phenotype prediction for HIV resistance testing. The prediction was achieved by performing a search in a database of genotype-phenotype pairs and matching the mutations in the database with those of the sample from the patient (Nearest neighbor search). A phenotype was predicted which provided information on the resistance of the virus to treatment.
Virco was founded in 1995 by Rudi Pauwels (Rega Institute for Medical Research) and Paul Stoffels (Janssen Pharmaceutica). The company built a database on all possible mutations of the AIDS virus and the ways in which drugs reacted to these mutations. The company acted as a partner to other companies such as LabCorporation. LabCorp. and others sent the blood samples of AIDS patients to Virco, where tests were carried out into the virus's possible resistance to the anti-HIV drugs. On 21 March 2002 the company was acquired by Johnson & Johnson.
- Larder BA, Kemp SD, Hertogs K. Quantitative prediction of HIV-1 phenotypic drug resistance from genotypes: the virtual phenotype (VirtualPhenotype), Antiviral Therapy. 2000;5 (suppl 3):49.
|This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.|